Trial Profile
A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs Pazopanib (Primary) ; Temsirolimus
- Indications Renal cell carcinoma
- Focus Therapeutic Use
- Acronyms TemPa
- 20 Sep 2019 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Results presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
- 10 Feb 2018 Primary endpoint has not been met. (Progression Free Survival (PFS)) as per result presented at the 2018 Genitourinary Cancers Symposium